Mineralys Therapeutics (MLYS) Non-Current Assets (2022 - 2026)

Mineralys Therapeutics has disclosed Non-Current Assets across 5 years of filings, most recently posting $392000.0 for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $392000.0, down 9.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 29.06% YoY), and the FY2025 annual result was $420000.0, down 23.91% from the prior year.
• Non-Current Assets came in at $392000.0 for Q1 2026 at Mineralys Therapeutics, down from $420000.0 in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $31.2 million in Q1 2023 to a low of $151000.0 in Q3 2025.
• The 5-year median for Non-Current Assets is $506000.0 (2024), against an average of $5.2 million.
• Across the five-year window, Non-Current Assets surged 55.3% in 2023 and sank 98.62% in 2024, its largest moves.
• Mineralys Therapeutics' Non-Current Assets stood at $1.6 million in 2022, then jumped by 55.3% to $2.5 million in 2023, then tumbled by 78.21% to $552000.0 in 2024, then dropped by 23.91% to $420000.0 in 2025, then retreated by 6.67% to $392000.0 in 2026.
• The last three Non-Current Assets figures came in at $392000.0 (Q1 2026), $420000.0 (Q4 2025), and $151000.0 (Q3 2025), per Business Quant data.